Interleukin 35: A novel candidate biomarker to diagnose early onset sepsis in neonates

Clinica Chimica Acta

Volumn 462, Issue , 2016, Pages 90-95

  Du, Wei Xia ^a,b,c   He, Yu ^a,b,c   Jiang, Hong Yan ^a,b,c   Ai, Qing ^a,b,c   Yu, Jia Lin ^a,b,c  

^a CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b ChongQing Intl Science and Technology Cooperation Center for Child Development and Disorders   (China)

^c CHONGQING KEY LABORATORY OF PEDIATRICS   (China)

Author keywords

Biomarker; Early onset sepsis; Interleukin 35; Neonate

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 35; PROCALCITONIN; BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN;

ABDOMINAL DISTENSION; APGAR SCORE; ARTICLE; BIRTH WEIGHT; BLOOD CULTURE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; EARLY DIAGNOSIS; EARLY ONSET SEPSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; KOLMOGOROV SMIRNOV TEST; LEUKOCYTE COUNT; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPSIS; SEX DIFFERENCE; BLOOD; NEONATAL SEPSIS;

BIOMARKERS; FEMALE; HUMANS; INFANT, NEWBORN; INTERLEUKINS; MALE; NEONATAL SEPSIS; PROSPECTIVE STUDIES;

EID: 84986880381     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.09.005     Document Type: Article

References (48)

1. [1] Liu, L., Oza, S., Hogan, D., Perin, J., Rudan, I., Lawn, J.E., et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 385:9966 (2015), 430–440.
2. [2] Liu, L., Johnson, H.L., Cousens, S., Perin, J., Scott, S., Lawn, J.E., et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379:9832 (2012), 2151–2161.
3. [3] Polin, R.A., F. Committee on, Newborn, Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics 129:5 (2012), 1006–1015.
4. [4] Peters, R.P.H., van Agtmael, M.A., Danner, S.A., Savelkoul, P.H.M., Vandenbroucke-Grauls, C.M.J.E., New developments in the diagnosis of bloodstream infections. Lancet Infect. Dis. 4:12 (2004), 751–760.
5. [5] Schelonka, R.L., Chai, M.K., Yoder, B.A., Hensley, D., Brockett, R.M., Ascher, D.P., Volume of blood required to detect common neonatal pathogens. J. Pediatr. 129:2 (1996), 275–278.
6. [6] Escobar, G.J., Puopolo, K.M., Wi, S., Turk, B.J., Kuzniewicz, M.W., Walsh, E.M., et al. Stratification of risk of early-onset sepsis in newborns >/= 34 weeks' gestation. Pediatrics 133:1 (2014), 30–36.
7. [7] Pierrakos, C., Vincent, J.-L., Sepsis biomarkers: a review. Crit. Care, 14(1), 2010, R15.
8. [8] Clark, R.H., Bloom, B.T., Spitzer, A.R., Gerstmann, D.R., Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics 117:1 (2006), 67–74.
9. [9] Cotten, C.M., McDonald, S., Stoll, B., Goldberg, R.N., Poole, K., Benjamin, D.K. Jr., et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 118:2 (2006), 717–722.
10. [10] Manzoni, P., Mostert, M., Galletto, P., Gastaldo, L., Gallo, E., Agriesti, G., et al. Is thrombocytopenia suggestive of organism-specific response in neonatal sepsis?. Pediatr. Int. 51:2 (2009), 206–210.
11. [11] Schmutz, N., Henry, E., Jopling, J., Christensen, R.D., Expected ranges for blood neutrophil concentrations of neonates: the Manroe and Mouzinho charts revisited. J. Perinatol. 28:4 (2008), 275–281.
12. [12] Benitz, W.E., Han, M.Y., Madan, A., Ramachandra, P., Serial serum C-reactive protein levels in the diagnosis of neonatal infection. Pediatrics, 102(4), 1998, E41.
13. [13] Prashant, A., Vishwanath, P., Kulkarni, P., Sathya Narayana, P., Gowdara, V., Nataraj, S.M., et al. Comparative assessment of cytokines and other inflammatory markers for the early diagnosis of neonatal sepsis-a case control study. PLoS One, 8(7), 2013, e68426.
14. [14] Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:7169 (2007), 566–569.
15. [15] Whitehead, G.S., Wilson, R.H., Nakano, K., Burch, L.H., Nakano, H., Cook, D.N., IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J. Allergy Clin. Immunol. 129:1 (2012), 207–215, e201–205.
16. [16] Huang, C.H., Loo, E.X., Kuo, I.C., Soh, G.H., Goh, D.L., Lee, B.W., et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J. Immunol. 187:1 (2011), 462–471.
17. [17] Egwuagu, C.E., Yu, C.R., Sun, L., Wang, R., Interleukin 35: critical regulator of immunity and lymphocyte-mediated diseases. Cytokine Growth Factor Rev. 26:5 (2015), 587–593.
18. [18] Cao, J., Xu, F., Lin, S., Tao, X., Xiang, Y., Lai, X., et al. IL-35 is elevated in clinical and experimental sepsis and mediates inflammation. Clin. Immunol. 161:2 (2015), 89–95.
19. [19] Gibot, S., Bene, M.C., Noel, R., Massin, F., Guy, J., Cravoisy, A., et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am. J. Respir. Crit. Care Med. 186:1 (2012), 65–71.
20. [20] Vouloumanou, E.K., Plessa, E., Karageorgopoulos, D.E., Mantadakis, E., Falagas, M.E., Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med. 37:5 (2011), 747–762.
21. [21] Yu, Z., Liu, J., Sun, Q., Qiu, Y., Han, S., Guo, X., The accuracy of the procalcitonin test for the diagnosis of neonatal sepsis: a meta-analysis. Scand. J. Infect. Dis. 42:10 (2010), 723–733.
22. [22] Jekarl, D.W., Kim, J.Y., Lee, S., Kim, M., Kim, Y., Han, K., et al. Diagnosis and evaluation of severity of sepsis via the use of biomarkers and profiles of 13 cytokines: a multiplex analysis. Clin. Chem. Lab. Med. 53:4 (2015), 575–581.
23. [23] Stocker, M., Fontana, M., El Helou, S., Wegscheider, K., Berger, T.M., Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 97:2 (2010), 165–174.
24. [24] Patel, S.J., Oshodi, A., Prasad, P., Delamora, P., Larson, E., Zaoutis, T., et al. Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance. Pediatr. Infect. Dis. J. 28:12 (2009), 1047–1051.
25. [25] Reed, E.E., Stevenson, K.B., West, J.E., Bauer, K.A., Goff, D.A., Impact of formulary restriction with prior authorization by an antimicrobial stewardship program. Virulence 4:2 (2013), 158–162.
26. [26] Bizzarro, M.J., Gallagher, P.G., Antibiotic-resistant organisms in the neonatal intensive care unit. Semin. Perinatol. 31:1 (2007), 26–32.
27. [27] Cotten, C.M., Taylor, S., Stoll, B., Goldberg, R.N., Hansen, N.I., Sanchez, P.J., et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 123:1 (2009), 58–66.
28. [28] Guerti, K., Devos, H., Ieven, M.M., Mahieu, L.M., Time to positivity of neonatal blood cultures: fast and furious?. J. Med. Microbiol. 60:Pt 4 (2011), 446–453.
29. [29] Ganatra, H.A., Stoll, B.J., Zaidi, A.K., International perspective on early-onset neonatal sepsis. Clin. Perinatol. 37:2 (2010), 501–523.
30. [30] Devergne, O., Birkenbach, M., Kieff, E., Epstein–Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc. Natl. Acad. Sci. U. S. A. 94:22 (1997), 12041–12046.
31. [31] Collison, L.W., Vignali, D.A., Interleukin-35: odd one out or part of the family?. Immunol. Rev. 226:1 (2008), 248–262.
32. [32] Olson, B.M., Sullivan, J.A., Burlingham, W.J., Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front. Immunol., 4, 2013, 315.
33. [33] Mao, H., Gao, W., Ma, C., Sun, J., Liu, J., Shao, Q., et al. Human placental trophoblasts express the immunosuppressive cytokine IL-35. Hum. Immunol. 74:7 (2013), 872–877.
34. [34] Collison, L.W., Chaturvedi, V., Henderson, A.L., Giacomin, P.R., Guy, C., Bankoti, J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 11:12 (2010), 1093–1101.
35. [35] Wirtz, S., Billmeier, U., Mchedlidze, T., Blumberg, R.S., Neurath, M.F., Interleukin-35 mediates mucosal immune responses that protect against t-cell–dependent colitis. Gastroenterology 141:5 (2011), 1875–1886.
36. [36] Bai, J., Qiu, S.L., Zhong, X.N., Huang, Q.P., He, Z.Y., Zhang, J.Q., et al. Erythromycin enhances CD4 + Foxp3 + regulatory T-cell responses in a rat model of smoke-induced lung inflammation. Mediat. Inflamm., 2012, 2012, 410232.
37. [37] Hotchkiss, R.S., Monneret, G., Payen, D., Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13:3 (2013), 260–268.
38. [38] Chen, Y., Wang, C.J., Lin, S.H., Zhang, M., Li, S.Y., Xu, F., Interleukin-35 is upregulated in response to influenza virus infection and secondary bacterial pneumonia. Cytokine 81 (2016), 23–27.
39. [39] Held, J., Preuße, C., Döser, A., Richter, L., Heppner, F.L., Stenzel, W., Enhanced acute immune response in IL-12p35 −/− mice is followed by accelerated distinct repair mechanisms in Staphylococcus aureus–induced murine brain abscess. J. Infect. Dis. 208:5 (2013), 749–760.
40. [40] Wirtz, S., Tubbe, I., Galle, P.R., Schild, H.J., Birkenbach, M., Blumberg, R.S., et al. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J. Exp. Med. 203:8 (2006), 1875–1881.
41. [41] Schlapbach, L.J., Graf, R., Woerner, A., Fontana, M., Zimmermann-Baer, U., Glauser, D., et al. Pancreatic stone protein as a novel marker for neonatal sepsis. Intensive Care Med. 39:4 (2013), 754–763.
42. [42] Makhoul, I.R., Yacoub, A., Smolkin, T., Sujov, P., Kassis, I., Sprecher, H., Values of C-reactive protein, procalcitonin, and Staphylococcus-specific PCR in neonatal late-onset sepsis. Acta Paediatr. 95:10 (2006), 1218–1223.
43. [43] Chiesa, C., Natale, F., Pascone, R., Osborn, J.F., Pacifico, L., Bonci, E., et al. C reactive protein and procalcitonin: reference intervals for preterm and term newborns during the early neonatal period. Clin. Chim. Acta 412:11 − 12 (2011), 1053–1059.
44. [44] Yang, A.P., Liu, J., Yue, L.H., Wang, H.Q., Yang, W.J., Yang, G.H., Neutrophil CD64 combined with PCT, CRP and WBC improves the sensitivity for the early diagnosis of neonatal sepsis. Clin. Chem. Lab. Med. 54:2 (2016), 345–351.
45. [45] Chiesa, C., Pellegrini, G., Panero, A., Osborn, J.F., Signore, F., Assumma, M., et al. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin. Chem. 49:1 (2003), 60–68.
46. [46] Turner, D., Hammerman, C., Rudensky, B., Schlesinger, Y., Goia, C., Schimmel, M.S., Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram. Arch. Dis. Child. Fetal Neonatal Ed. 91:4 (2006), F283–F286.
47. [47] Lopez Sastre, J.B., Solis, D.P., Serradilla, V.R., Colomer, B.F., Cotallo, G.D., Grupo de Hospitales, C., Evaluation of procalcitonin for diagnosis of neonatal sepsis of vertical transmission. BMC Pediatr., 7, 2007, 9.
48. [48] Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M., et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:8 (2016), 801–810.